Skip to main
EXAS

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences has demonstrated a positive growth trajectory with a significant 22% year-over-year increase in its core screening business driven primarily by the Cologuard test, which is expected to continue gaining market share towards its long-term goal of over 40%. The company has raised its 2025 revenue guidance following strong performance, with contributions expected from higher average selling prices of Cologuard Plus and continued adoption of its products, while also making strides towards achieving positive Adjusted EBITDA. With a target to screen at least 30 million people by 2027, a threefold increase from previous levels, and the introduction of a digital marketing campaign for its Cancerguard blood test, Exact Sciences is positioning itself for robust future growth in the oncology diagnostics market.

Bears say

Exact Sciences faces a negative outlook due to its dependence on promotional marketing spending to drive demand for its Cologuard test, indicating a vulnerability in its revenue streams. The company has a history of net losses, raising concerns about its ability to achieve and maintain GAAP profitability in the future. Furthermore, the projected revenue for 2027 of $4.0 billion falls short of expectations, which, combined with the recent downgrades in rating due to the announced acquisition, suggests potential challenges in financial stability and growth.

Exact Sciences (EXAS) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 18 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.